PTC Therapeutics

PTCT

Market cap $6.21B

PTC Therapeutics, Inc. (PTCT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

– Strong Sephience™ (sepiapterin) launch continues with unaudited Q4 global revenue of $92.5M – – Unaudited 2025 total product and royalty revenue of approximately $823M, exceeding guidance – – 2026 product revenue guidance of $700 – 800M, representing 19 – 36% year-over-year growth – – Strong cash position of approximately $1.94B as of December 31 – WARREN, N.J., Jan. 12, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today provided an update on the Company's progress and its outlook for 2026.

WARREN, N.J., Jan. 8, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 2, 2026, the company approved 300 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to a new non-executive employee.

– Indication includes all ages and the full spectrum of disease severity – – First Japan product approval for PTC – WARREN, N.J. , Dec. 22, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that Sephience™ (sepiapterin) has been approved by the Japanese Ministry of Health, Labor and Welfare (MHLW) for the treatment of children and adults living with phenylketonuria (PKU).

WARREN, N.J. , Dec. 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 16, 2025, the company approved non-statutory stock options to purchase an aggregate of 3,825 shares of its common stock and 4,385 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to five new employees.

WARREN, N.J. , Dec. 18, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that CEO Matthew B.

PTC Therapeutics, Inc. (PTCT) Presents at Citi Annual Global Healthcare Conference 2025 Transcript

California-based Palo Alto Investors increased its stake in PTCT by 456,144 shares in the third quarter, adding approximately $33.1 million in value. The change represents approximately 4.4% of reportable assets under management.

PTC Therapeutics, Inc. (PTCT) Discusses Progress in Small Molecule Splicing and Ferroptosis Platforms Transcript

PTC's strong third quarter and breakout Sephience launch may help explain why one life-sciences fund is quietly upping its bet.